CLPTM1L-shRNA2

CLPTM1L-shRNA2 is a specific short hairpin RNA (shRNA) construct designed to silence the expression of the Cleft Lip and Palate Transmembrane Protein 1-Like (CLPTM1L) gene. CLPTM1L, also known as CRR9, is a transmembrane protein frequently overexpressed in various malignancies, including cervical, lung, and pancreatic cancers, where it is associated with anti-apoptotic signaling and resistance to DNA-damaging agents like cisplatin. By utilizing the RNA interference (RNAi) pathway, CLPTM1L-shRNA2 targets CLPTM1L mRNA for degradation, leading to a significant reduction in protein levels. This knockdown has been shown in preclinical studies to inhibit tumor cell proliferation, induce apoptosis, and increase the sensitivity of cancer cells to chemotherapeutic treatments. It is primarily used as a research tool to investigate the functional role of CLPTM1L in oncogenesis and as a potential therapeutic lead for gene-silencing interventions.